Coronary heart disease.
Conditions
Interventions
Intervention 1: Control group: Placebo capsules produced by the pharmaceutical company producing the study supplements (Dana Pharmaceutical Company) and contain all the ingredients used in the supplem
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who are candidates for open heart surgery
Exclusion criteria
Exclusion criteria: Off-pump heart surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin 17 interferon gamma concentration. Timepoint: Measurement of cytokine concentration at the beginning of the study (before surgery) and 21 days after surgery. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Post surgery length of hospitalization. Timepoint: After open heart surgery. Method of measurement: Medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Makiabadi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed